Enterprise Value to EBITDA (EV/EBITDA)
Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)
Boston Scientific Corp., EBITDA calculation
US$ in millions
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
| Item | Description | The company |
|---|---|---|
| EBITDA | To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital. | Boston Scientific Corp. EBITDA increased from 2020 to 2021 and from 2021 to 2022. |
Enterprise Value to EBITDA Ratio, Current
Boston Scientific Corp., current EV/EBITDA calculation, comparison to benchmarks
| Selected Financial Data (US$ in millions) | |
| Enterprise value (EV) | 82,681) |
| Earnings before interest, tax, depreciation and amortization (EBITDA) | 2,747) |
| Valuation Ratio | |
| EV/EBITDA | 30.10 |
| Benchmarks | |
| EV/EBITDA, Competitors1 | |
| Abbott Laboratories | 22.64 |
| Cigna Group | 11.72 |
| CVS Health Corp. | 10.15 |
| Elevance Health Inc. | 8.56 |
| Intuitive Surgical Inc. | 57.70 |
| Medtronic PLC | 16.87 |
| UnitedHealth Group Inc. | 17.98 |
| EV/EBITDA, Sector | |
| Health Care Equipment & Services | 15.11 |
| EV/EBITDA, Industry | |
| Health Care | 15.96 |
Based on: 10-K (reporting date: 2022-12-31).
1 Click competitor name to see calculations.
If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.
Enterprise Value to EBITDA Ratio, Historical
Boston Scientific Corp., historical EV/EBITDA calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Enterprise value (EV)1 | 75,700) | 69,502) | 62,324) | 65,513) | 62,154) | |
| Earnings before interest, tax, depreciation and amortization (EBITDA)2 | 2,747) | 2,510) | 1,405) | 2,171) | 2,557) | |
| Valuation Ratio | ||||||
| EV/EBITDA3 | 27.56 | 27.69 | 44.36 | 30.18 | 24.31 | |
| Benchmarks | ||||||
| EV/EBITDA, Competitors4 | ||||||
| Abbott Laboratories | 15.85 | 17.42 | 25.99 | — | — | |
| Cigna Group | 8.88 | 9.06 | 6.31 | — | — | |
| CVS Health Corp. | 12.42 | 10.41 | 8.56 | — | — | |
| Elevance Health Inc. | 10.26 | 10.05 | 7.57 | — | — | |
| Intuitive Surgical Inc. | 41.52 | 44.54 | 59.12 | — | — | |
| Medtronic PLC | 14.99 | 24.41 | 17.92 | 16.01 | — | |
| UnitedHealth Group Inc. | 15.11 | 17.39 | 13.39 | — | — | |
| EV/EBITDA, Sector | ||||||
| Health Care Equipment & Services | 13.98 | 15.40 | 13.12 | — | — | |
| EV/EBITDA, Industry | ||||||
| Health Care | 13.71 | 13.87 | 16.50 | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
3 2022 Calculation
EV/EBITDA = EV ÷ EBITDA
= 75,700 ÷ 2,747 = 27.56
4 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| EV/EBITDA | Enterprise value to earnings before interest, tax, depreciation and amortization is a valuation indicator for the overall company rather than common stock. | Boston Scientific Corp. EV/EBITDA ratio decreased from 2020 to 2021 and from 2021 to 2022. |